Sarcopenia

Why you shouldn’t be afraid to start running after middle age

Retrieved on: 
Friday, April 19, 2024
Knee, Atrophy, Pressure, MRI, Osteopenia, Exercise, Walking, Activity, Cell, Bone marrow, Chemical oxygen demand, Risk, Gamer, Research, Sarcopenia, Running, Rest, Joint, Volunteering, Life, Arthritis, Osteoporosis, Spine, Bed rest, Cartilage, Osteoarthritis, Skeleton, Dietary supplement

As someone who started marathon running in mid-life, I know how many aches and pains (and doubts) you can have if you take on the challenge to start running at an older age.

Key Points: 
  • As someone who started marathon running in mid-life, I know how many aches and pains (and doubts) you can have if you take on the challenge to start running at an older age.
  • Hobbling around my orthopaedic hospital after my first marathon actually led me to do research on runners.
  • The high-resolution MRI scans found most of the 115 middle-aged participants had abnormalities in their knees before starting marathon training.
  • But while osteoarthritis is more common after middle age, it may actually be a lack of activity that leads to osteoarthritis.
  • Reduced muscle use, whether it is through inactivity or sarcopenia or both, also reduces the production of anti-inflammatory myokines from the muscles.
  • These chemicals are released when we exercise, and help reduce joint swelling and calm irritated joint linings.
  • This effect is pronounced in runners because running uses some of the largest muscles in the body – such as the glutes, quadriceps and hamstrings.

Where to begin

  • If you want to start running, the main message is to ease into it to reduce the risk of injury.
  • One of the best ways to ease into running in mid-life is the NHS Couch to 5K running programme.
  • It’s a free guide that will help you gradually work up towards running 5km in just nine weeks.
  • If you’ve experienced any of these problems, you’ll want to be careful when exercising to avoid further damage.


Alister Hart receives funding from 3 charities: The Rosetrees Trust, Arthroplasty for Arthritis and The Maurice Hatter Foundation.

Biophytis announces its 2023 financial results and provides an update on its business activities

Retrieved on: 
Wednesday, April 10, 2024
Annual, Notifiable disease, Annual report, Conference, Obesity, Euronext Growth, Goldman Sachs, Disease, MDA, Partnership, Risk, COVID-19, Patient, Duchenne muscular dystrophy, Sarcopenia, University, Respiratory failure, Clinical trial, Therapy, FDA, Pharmaceutical industry

2024: The actual start of the study will depend on the conclusion of partnership agreements and Biophytis' financial resources.

Key Points: 
  • 2024: The actual start of the study will depend on the conclusion of partnership agreements and Biophytis' financial resources.
  • Promising preclinical results for BIO101 (20-hydroxyecdysone) in obesity, suggesting beneficial metabolic effects on muscle and fat mass.
  • On this basis, Biophytis plans to start a phase 1/2 clinical trial in 2024, depending on its financial resources.
  • There is therefore significant doubt about the Company's ability to continue its business activities.

Biophytis announces its 2023 financial results and provides an update on its business activities

Retrieved on: 
Wednesday, April 10, 2024
Annual, Notifiable disease, Annual report, Conference, Obesity, Euronext Growth, Goldman Sachs, Disease, MDA, Partnership, Risk, COVID-19, Patient, Duchenne muscular dystrophy, Sarcopenia, University, Respiratory failure, Clinical trial, Therapy, FDA, Pharmaceutical industry

2024: The actual start of the study will depend on the conclusion of partnership agreements and Biophytis' financial resources.

Key Points: 
  • 2024: The actual start of the study will depend on the conclusion of partnership agreements and Biophytis' financial resources.
  • Promising preclinical results for BIO101 (20-hydroxyecdysone) in obesity, suggesting beneficial metabolic effects on muscle and fat mass.
  • On this basis, Biophytis plans to start a phase 1/2 clinical trial in 2024, depending on its financial resources.
  • There is therefore significant doubt about the Company's ability to continue its business activities.

Biophytis presented its phase 3 protocol in the treatment of sarcopenia

Retrieved on: 
Wednesday, April 10, 2024
Notifiable disease, Disability, Conference, Euronext Growth, Per, Risk, Patient, Sarcopenia, Ageing, Adapted automobile, Safety, Therapy, Poster, Metre, Pharmaceutical industry

The SARA-INT phase 2 study showed promising results on physical performance, with significant improvement in the 400 Meter Walking Test, reaching 0.07 m/s in the Full Analysis Set population and 0.09 m/s in the Per Protocol population.

Key Points: 
  • The SARA-INT phase 2 study showed promising results on physical performance, with significant improvement in the 400 Meter Walking Test, reaching 0.07 m/s in the Full Analysis Set population and 0.09 m/s in the Per Protocol population.
  • Based on outcome of the SARA-INT phase 2 study and on results from the SPRINTT and LIFE studies, Biophytis designed an interventional, randomized, double-blind, placebo-controlled clinical phase 3 study (the SARA-31 study), expected to include 932 subjects.
  • The poster presented at the ICFSR conference, which details the objectives and the design of the study, can be viewed by clicking on this link .
  • Stanislas Veillet, CEO of Biophytis, stated: "The SARA-31 phase 3 study will assess the efficacy and safety of RuvembriTM in the treatment of sarcopenic patients at risk of functional decline and disability.

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)

Retrieved on: 
Wednesday, April 10, 2024
Notifiable disease, Metabolism, Obesity, Euronext Growth, Skeletal muscle, Patient, Nature Biotechnology, Weight loss, Trial of the century, OBA, Facial muscles, Sarcopenia, Therapy, MAS, Pharmaceutical industry

These benefical effects of BIO101 (20-hydroxyecdysone) may translate into improved mobility and muscle strength in obese sarcopenic patients, as suggested in the SARA-INT phase 2 study.

Key Points: 
  • These benefical effects of BIO101 (20-hydroxyecdysone) may translate into improved mobility and muscle strength in obese sarcopenic patients, as suggested in the SARA-INT phase 2 study.
  • We believe that our leadership in developing drugs for muscular diseases and promising results obtained in obesity will be a strong accelerator of the OBA clinical plan."
  • The OBA Phase 2 clinical study is expected to start mid 2024, upon regulatory approvals, with first patients expected to be treated in the second half of 2024.
  • Further information on the OBA program and the clinical study is expected to be provided through the coming weeks.

Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 27, 2024
Research, Blood pressure, Body composition, LDL, Adipose tissue, Obesity, Development, Cirrhosis, Three Months, Exercise, Arrhythmia, Hepatitis B virus, Diabetes, Lipid, Patient, Heart rate, Fast Track, Weight loss, Sarcopenia, MASH, Woman, Diet, Investment, Fibrosis, Safety, Optimism, FDA, Triglyceride, IMPACT, Dietary supplement

“We are extremely pleased with the results of the body composition analysis from our recently completed MOMENTUM 48-week Phase 2 obesity trial of pemvidutide.

Key Points: 
  • “We are extremely pleased with the results of the body composition analysis from our recently completed MOMENTUM 48-week Phase 2 obesity trial of pemvidutide.
  • “There is a growing appreciation that the quality of weight loss is as important as the quantity of weight loss.
  • Achieved mean weight loss of 15.6% on 2.4 mg dose of pemvidutide at week 48, with weight loss continuing at the end of treatment.
  • Financial Results for the Three Months Ended December 31, 2023
    Altimmune had cash, cash equivalents and short-term investments totaling $198.0 million at December 31, 2023.

Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit

Retrieved on: 
Thursday, March 14, 2024
CELU, Cell, Tissue, Research, Sarcopenia, Cornell University, Cancer, Biology, Pulse, Regenerative medicine, Immunity, Placenta, Singularity Group, Immunosenescence, Movement, Autoimmunity, Ageing, Medicine

Dr. Hariri’s presentation, titled “The Cell Therapy Basis for Longevity,” will discuss the potential for using cellular therapeutics to address the biological ravages of aging by combating immunosenescence, sarcopenia and degenerative diseases.

Key Points: 
  • Dr. Hariri’s presentation, titled “The Cell Therapy Basis for Longevity,” will discuss the potential for using cellular therapeutics to address the biological ravages of aging by combating immunosenescence, sarcopenia and degenerative diseases.
  • Dr. Hariri has led the effort to harness the unique biology of placental-derived cells in a range of clinical indications, including cancer, autoimmune and degenerative diseases.
  • “Dr.
  • This work puts Dr. Hariri at the forefront of the longevity movement, with his finger on the pulse of the ever-changing landscape.”
    The ABUNDANCE Summit will occur in Los Angeles, Calif., from March 17 through 21, 2024.

Immunis Discusses with Experts Why the Immune System is the Key to Human Healthspan

Retrieved on: 
Friday, April 5, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Health Technology, Clinical Trials, Immune system, Human, Notifiable disease, Therapy, Muscle atrophy, Multimedia, Metabolism, Sarcopenia, Facial muscles, DSM-IV codes, Cell, Inc., Vaccine

View the full release here: https://www.businesswire.com/news/home/20240405602477/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240405602477/en/
    “Aging is a manifestation of immune decline.
  • This staggering statistic emphasizes the need for interventions that restore immune function to prevent the onset of such diseases.
  • By focusing on the prevention of immune dysregulation and the maintenance of immune health, Immunis aims to empower individuals to take charge of how they age.
  • Immunis aims to ignite a conversation on the profound benefits of nurturing the immune system for a transformative impact on muscle health and ultimately, human healthspan.

Immunis Chairman Dr. Hans Keirstead to Present Abundance360 Moonshot

Retrieved on: 
Monday, March 18, 2024
Surgery, Other Health, Other Science, Pharmaceutical, Oncology, Medical Devices, Infectious Diseases, Hospitals, Technology, Fitness & Nutrition, Clinical Trials, Stem Cells, Women, Science, Biotechnology, Practice Management, Seniors, Physical Therapy, Nanotechnology, Alternative Medicine, Managed Care, Medical Supplies, Men, FDA, Health, Diabetes, Consumer, Notifiable disease, Longevity, Facial muscles, Education, Patient, Ageing, Research, Sarcopenia, DSM-IV codes, Aging Cell, Quality of life, Human, Regenerative medicine, Safety, Fix, Muscle atrophy, Dietary supplement

Immunis, Inc., a private biotech company developing an innovative secretome for age-related diseases and immune dysfunction, announces that its Chairman, Dr. Hans Keirstead, will present at the annual Abundance360 in Los Angeles.

Key Points: 
  • Immunis, Inc., a private biotech company developing an innovative secretome for age-related diseases and immune dysfunction, announces that its Chairman, Dr. Hans Keirstead, will present at the annual Abundance360 in Los Angeles.
  • In fact, Abundance360 showcases “Moonshots,” or transformative ideas, from leaders who are making excellent strides to revolutionize human healthspan.
  • Dr. Keirstead’s Moonshot aims for the incredible goal of one day treating 500M individuals with Immunis’ investigational secretome (IMMUNA) to combat age-related immune dysfunction, targeting muscle atrophy and metabolic decline.
  • Dr. Keirstead’s Moonshot with IMMUNA aligns perfectly with his “Massive Transformative Purpose” to democratize regenerative medicine and enable everyone to live healthier lives.

Lincoln Property Company, BPGbio, and Cresa Announce 70,000-sq.-ft. Lease at 300 Third Avenue in Waltham

Retrieved on: 
Wednesday, February 21, 2024
Commercial Building & Real Estate, Construction & Property, Technology, Consulting, Pharmaceutical, Oncology, Professional Services, Neurology, Artificial Intelligence, Clinical Trials, Science, Biotechnology, Software, Health, Research, Senior, Culture, SCC, Epidermolysis bullosa, Pancreatic cancer, Sarcopenia, Cresa, Gold, Greater, Property, LEED, EB, Netherlands Architecture Institute, Lease administration, Knight Frank, Biology, Red Line (MBTA), Partnership, Therapy, Breast cancer, Multimedia, Capital market, Liver disease, Carcinoma, Type, Third, Lincoln, Quality of life, Government, GBM, Patient, Medicine, Glioblastoma, Business transaction management, Engineered wood

ft. of lab and office space at 300 Third Avenue in Waltham, Mass.

Key Points: 
  • ft. of lab and office space at 300 Third Avenue in Waltham, Mass.
  • View the full release here: https://www.businesswire.com/news/home/20240221278304/en/
    300 Third Avenue in Waltham, Massachusetts.
  • 300 Third Avenue is a 143,533-sq.-ft. purpose-built life science building with four stories of laboratory space and 441 on-site parking spaces.
  • Lincoln Property Company (“Lincoln”) is one of the largest diversified real estate services companies with 35 offices across the United States the United Kingdom and Europe.